MOREL DONALD E JR sold $26K of STVN

MOREL DONALD E JR sold 1,493 shares of Stevanato Group S.p.A. (STVN) at $17.09 on 2026-06-15.

Original reporting
SEC EDGAR · MOREL DONALD E JR
Published Jun 26, 2026, 10:12 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 26, 2026, 10:33 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$STVN
Neutral
high confidence
Mentioned
$STVN
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$STVNNeutralLow
01

Why it matters

The newest fact is the director’s open-market sale details (shares, price, total value, and post-transaction holdings). This can marginally influence sentiment but does not change the company’s fundamentals based on the provided text.

02

Market read

Traders may note insider selling as a minor sentiment input, but there is no new guidance, deal, or operational datapoint here.

03

What to watch

The article does not state whether other insiders sold/bought around the same time, nor does it provide context on total compensation or prior holdings beyond the post-transaction share count.

Relevance 3/10Novelty 3/10Timing: Form 4 filed 2026-06-26 (sale dated 2026-06-15)

Background

The article is a primary-source SEC Form 4 insider transaction disclosure for Stevanato Group S.p.A.

Company-level read

Ticker impact

$STVNNeutralHigh confidence
Context

Stevanato Group director MOREL DONALD E JR filed a Form 4 open-market sale of 1,493 shares at $17.09 on 2026-06-15.

Expected impact

Low likelihood of a sustained price move solely from this Form 4 sale; any impact is likely short-lived.

Evidence & confidence

The filing is a small, disclosed open-market sale with no 10b5-1 plan and no accompanying fundamental news in the text.

Market effects

No sector-level implications; this is company-specific insider transaction data only.

None indicated.

None indicated.

Counterpoint

Insider sales can be tax- or diversification-driven and may not reflect bearish fundamentals, especially when the transaction is disclosed as open-market.

Key entities

  • Stevanato Group S.p.A.

    Subject of the Form 4 insider transaction disclosure (STVN).

  • MOREL DONALD E JR

    Director who sold 1,493 shares in an open-market sale; filing reported via SEC EDGAR.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$STVNHighAI 8/10

Stevanato Group Q3 Earnings Call Highlights

Stevanato Group (STVN) expects 2027 revenue growth to moderate to low-single-digit due to GLP-1-related headwinds, but believes growth will normalize beyond 2027. The company reaffirmed its 2026 guidance, forecasting revenue of €1.26B-€1.28B and adjusted EBITDA of €335M-€345.2M. It is ramping up manufacturing investments and working on over 50 GLP-1-related programs with 30 global customers.

$STVNMed

Stevanato (STVN) Q3 2026 Earnings Call Transcript

Stevanato (STVN) reported Q3 2026 earnings, with non-GLP biologics revenue up 30% offsetting GLP-1 declines. Full-year non-GLP biologics revenue rose 13%. The company expects lower GLP volumes in 2027 but strong demand in non-GLP biologics. They are backfilling revenue and expanding production capacity. Engineering segment results were below expectations, but BDS segment performance will offset this.

$STVNMed

Stevanato Group SpA (STVN) (Q3 2026) Earnings Call Highlights: Revenue Climbs 8%

Stevanato Group SpA (STVN) reported Q3 2026 revenue growth of 8%, but expects lower GLP-1 volumes in 2027 from a single customer, moderating growth. Engineering segment revenue declined 12%, and gross profit margin decreased to 29.1%. The company backfilled most GLP-1 shortfall but expects validation delays. Non-GLP biologics grew 30% in Q3, driven by broad engagement and capacity investments. Alina pen injector and other delivery devices are in validation stages.

$STVNMed

Stevanato Group S.p.A. (STVN): Financial results for Q3 2026

Stevanato Group S.p.A. (STVN) furnished an SEC Form 6-K — earnings release. EXHIBIT 99.1 Stevanato Group Delivers 8% Revenue Growth for the Third Quarter of Fiscal 2026 - The Company Maintains Fiscal Year 2026 Guidance - (PIOMBINO DESE, Italy) – November 3, 2026 – Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug de

HighAI 8/10

Why is Stevanato stock plunging today?

Stevanato Group's stock fell 25.5% to $14.71 after reporting Q3 2026 revenue of €326.1M, up 8% YoY, beating estimates. However, the outlook for 2027 revenue growth was cut to low single digits due to reduced GLP-1-related volumes from a large customer, alarming investors. The company maintained its full-year 2026 revenue guidance of €1.26B to €1.28B.